Trial Profile
Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 31 Oct 2021 Results published in the Targeted Oncology
- 25 Jan 2020 Primary endpoint (3-Month Progression Free Survival Rate ) has been met as per Results presented at the 2020 Gastrointestinal Cancers Symposium.
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.